Hims & Hers Health, Inc. $HIMS Shares Sold by Aviva PLC

Aviva PLC cut its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 48.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,963 shares of the company’s stock after selling 7,424 shares during the quarter. Aviva PLC’s holdings in Hims & Hers Health were worth $397,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HIMS. Los Angeles Capital Management LLC grew its holdings in Hims & Hers Health by 163.3% during the second quarter. Los Angeles Capital Management LLC now owns 98,155 shares of the company’s stock worth $4,893,000 after acquiring an additional 60,878 shares during the period. Prospera Financial Services Inc purchased a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $402,000. Summit Investment Advisors Inc. boosted its position in shares of Hims & Hers Health by 187.0% during the 1st quarter. Summit Investment Advisors Inc. now owns 56,971 shares of the company’s stock valued at $1,683,000 after acquiring an additional 37,118 shares during the last quarter. AE Wealth Management LLC acquired a new position in Hims & Hers Health in the second quarter valued at approximately $292,000. Finally, Forbes Financial Planning Inc. purchased a new stake in Hims & Hers Health in the 2nd quarter valued at about $241,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on HIMS. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. BTIG Research reiterated a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, UBS Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health has an average rating of “Reduce” and a consensus price target of $45.27.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 900 shares of the business’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the completion of the sale, the insider directly owned 291,439 shares in the company, valued at $16,976,321.75. The trade was a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,637 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $42.53, for a total value of $112,151.61. Following the completion of the sale, the insider owned 155,856 shares of the company’s stock, valued at approximately $6,628,555.68. This represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 712,336 shares of company stock valued at $37,611,319. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Up 2.9%

Shares of NYSE HIMS opened at $37.09 on Friday. The firm’s 50 day moving average price is $50.63 and its 200 day moving average price is $51.22. Hims & Hers Health, Inc. has a 1 year low of $19.15 and a 1 year high of $72.98. The firm has a market cap of $8.44 billion, a P/E ratio of 68.68, a price-to-earnings-growth ratio of 7.18 and a beta of 2.20. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.Hims & Hers Health’s revenue was up 49.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.